Multiple Myeloma Clinical Trial
Now Enrolling: K36-MMSET-001 Clinical Trial for Relapsed/Refractory Multiple Myeloma
We are actively enrolling t(4;14) patients in the US, Canada, France & Spain in our Phase 1 clinical trial evaluating KTX-1001, a selective NSD2 inhibitor, in combination with standard of care and novel iMiD for early relapsed/refractory multiple myeloma (rrMM).
Dose Expansion Cohorts are Now Open
To learn more and to find a research center near you, please visit:
www.clinicaltrials.gov (NCT05651932).
Prostate Cancer Clinical Trial
STRIKE-001 Phase 1 Clinical Trial is NOW Enrolling in the U.S.
Our first-in-human Phase 1 study, STRIKE-001 is recruiting participants. This trial is evaluating KTX-2001, a selective NSD2 inhibitor, as monotherapy and in combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
To learn more about the study and recruiting clinical research centers, please visit: www.clinicaltrials.gov (NCT07103018).
To potentially enroll in one of the above clinical trials, Patients should discuss with their doctor whether they qualify for one of the above k36 clinical trials.